Twin Cities, MN— October 3rd, 2023 — Biomedix, a market-leading medical technology and innovation company, is proud to announce research support for Memorial Sloan Kettering Cancer Center (MSKCC), a world leader in patient care, research, and educational program.
Dr. Yolanda Bryce, MD, RPVI is serving as the Principal Investigator for this project, designed to screen for Peripheral Artery Disease (PAD) in cancer patients who are having surgery. Biomedix’s PADnet technology is being used to help discover the prevalence of PAD within this population, and help MSKCC compare cancer outcomes of cancer patients with PAD versus those who do not have PAD.
“We reviewed a number of technologies to screen for PAD,” said Dr. Bryce, “and decided to go with PADnet for a few reasons, including Biomedix’s market leadership in this space. We really liked the fact that PADnet studies can be performed by a medical assistant, the fact that service and training is included with the technology, and the centralized data platform.”
“We are excited to be the chosen PAD technology partner for a world-class organization like Memorial Sloan Kettering,” said Chris Trygstad, VP of Product at Biomedix, “we believe that breaking down data silos through the automated aggregation of diagnostic data on a unified, HITRUST-certified web service platform, makes our offering ideal for research studies involving chronic conditions.”
Dr. Bryce added, “This research will enable us to further investigate racial disparities in PAD and amputation rates. We know that PAD prevalence is higher in under-served groups, and want to establish the benefit of PAD screening in high-prevalence communities”.
“We are committed to the cause of ending racial disparities in healthcare,” added John Romans, CEO of Biomedix, “and are proud to be able to contribute to this project. Our most recent offerings have the ability to evaluate Social Determinants of Health (SDoH) at the point-of-care, and aggregate this data as well, and we’re hoping that our technology can help improve patient outcomes across races and socio-economic backgrounds.”
About Biomedix
Biomedix is a provider of front-line diagnostic solutions for delivering value-based care. Biomedix Xchange is a population health solution that centralizes data for analyzing population health across multiple chronic conditions. For more information, visit Biomedix.com.
About PADnet & PADnet Xpress
Biomedix is the maker of PADnet, the market leader in front-line diagnostics for peripheral vascular disease. PADnet is the only diagnostic device that can support the identification of PAD and chronic venous insufficiency (CVI) through a unique collaborative care model. PADnet Xpress represents the latest technology for quick and accurate PAD detection, custom-designed for value-based care, including Medicare Advantage Organizations (MAOs).
